TD Cowen analyst Charles Rhyee lowered the firm’s price target on Charles River (CRL) to $197 from $205 and keeps a Buy rating on the shares. The firm said the company’s strategic review update suggests a full Mfr. sale is unlikely, and the reality is DSA revenue growth will be challenged in 2026, with the base case being revenue growth down.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Buy Rating for Charles River Labs: Potential Upside Amid Dynamic Environment and Favorable Trends
- Charles River price target raised to $165 from $160 at JPMorgan
- Charles River upgraded to Outperform from Neutral at Baird
- Charles River Laboratories Reports Q3 2025 Earnings
- Charles River Labs Earnings Call: Mixed Sentiments and Strategic Moves